Amendments to the claims

1-19 (Cancelled)

20. (Currently Amended) A process to prepare pharmaceutical tablets containing paroxetine, on a commercial scale, which process comprises the steps of:

a) dry admixing paroxetine and dry excipients in a mixer to form a mixture; or

b) dry admixing paroxetine and dry excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and

c) compressing the mixture into tablets;

provided that the excipients include ~~at least one of;~~ sodium starch glycollate, dicalcium phosphate and magnesium stearate.

21. (Currently Amended) A process to prepare pharmaceutical tablets containing paroxetine, on a commercial scale, which process comprises the steps of:

a) dry admixing paroxetine and dry excipients in a mixer to form a mixture; or

b) dry admixing paroxetine and dry excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and

c) compressing the mixture into tablets;

provided that the excipients include ~~at least one of;~~ sodium starch glycollate, dicalcium phosphate and magnesium stearate;

and further provided that one of the excipients that is compressed into tablets is not microcrystalline cellulose.

22. (Previously Presented) A process according to claim 20 in which the amount of paroxetine in each tablet is selected from: 10 mg, 20 mg, 30 mg, 40 mg and 50 mg, wherein the amount of paroxetine is expressed as the free base.

23. (Previously Presented) A process according to claim 21 in which the amount of paroxetine in each tablet is selected from: 10 mg, 20 mg, 30 mg, 40 mg and 50 mg, wherein the amount of paroxetine is expressed as the free base.

24. (Previously Presented) A process according to claim 22 in which the amount of paroxetine in each tablet is about 10 mg, wherein the amount of paroxetine is expressed as the free base.

25. (Previously Presented) A process according to claim 23 in which the amount of paroxetine in each tablet is about 10 mg, wherein the amount of paroxetine is expressed as the free base.

26. (Previously Presented) A process according to claim 22 in which the amount of paroxetine in each tablet is about 20 mg, wherein the amount of paroxetine is expressed as the free base.

27. (Previously Presented) A process according to claim 23 in which the amount of paroxetine in each tablet is about 20 mg, wherein the amount of paroxetine is expressed as the free base.

28. (Previously Presented) A process according to claim 22 in which the amount of paroxetine in each tablet is about 30 mg, wherein the amount of paroxetine is expressed as the free base.

E1 cancel

29. (Previously Presented) A process according to claim 23 in which the amount of paroxetine in each tablet is about 30 mg, wherein the amount of paroxetine is expressed as the free base.

30. (Previously Presented) A process according to claim 22 in which the amount of paroxetine in each tablet is about 40 mg, wherein the amount of paroxetine is expressed as the free base.

31. (Previously Presented) A process according to claim 23 in which the amount of paroxetine in each tablet is about 40 mg, wherein the amount of paroxetine is expressed as the free base.

32. (Previously Presented) A process according to claim 22 in which the amount of paroxetine in each tablet is about 50 mg, wherein the amount of paroxetine is expressed as the free base.

33. (Previously Presented) A process according to claim 23 in which the amount of paroxetine in each tablet is about 50 mg, wherein the amount of paroxetine is expressed as the free base.